Anupam Rasayan India Limited – Investor Presentation Summary
Key Operational Highlights
- Delivered the highest-ever quarterly consolidated revenue of ₹812 Cr, registering 10% YoY growth
- Consolidated EBITDA grew by 41% YoY to ₹202 Cr, with margins improving to 25% from 19%
- Generated operating cash flow of ₹328 crore as of September 2026, compared to ₹334 crore as of March 2026
- Strong manufacturing footprint with 14+ manufacturing facilities across India and USA
- 200+ clients served globally with exports to 14+ countries
Key drivers of operational performance:
Higher contribution from high-margin Performance Materials and Pharmaceutical products, improved working capital management, and strategic acquisitions.
Segment-wise Performance
- Life Science Related Specialty Chemicals: Agrochemicals, Personal Care, and Pharmaceuticals intermediates
- Performance Materials: Polymer and Electronic Chemicals segments
- Other Fluorinated Products (Tanfac): Portfolio of fluorine-based chemicals including Hydrofluoric Acid and derivatives
Explanation of significant changes in segment performance:
Growth driven by diversified product portfolio across multiple verticals including agrochemicals, pharmaceuticals, performance materials, and fluorinated products.
Financial Highlights
Revenue: ₹821 Cr (Consolidated Q2FY27), ₹1,489 Cr (Consolidated H1FY27)
EBITDA: ₹202 Cr (Consolidated Q2FY27), ₹377 Cr (Consolidated H1FY27)
PAT: ₹65 Cr (Consolidated Q2FY27), ₹116 Cr (Consolidated H1FY27)
EPS: ₹6.81 (Consolidated Q2FY27), ₹10.21 (Consolidated H1FY27)
Margins: EBITDA Margin 25% (Q2FY27), PAT Margin 8% (Q2FY27)
YoY/QoQ comparison: Q2 Consolidated Revenue grew 11% YoY and 23% QoQ; Q2 Consolidated PAT grew 14% YoY and 27% QoQ
Drivers of financial performance:
Higher revenue growth, improved product mix with higher contribution from high-margin products, and operational efficiencies.
Key Risks:
Not explicitly disclosed in the presentation.
Geographical Revenue Split
Domestic vs Export/Regional Revenue: Not specified in exact figures
Regional Breakdown: Exports to 14+ countries including Japan, Switzerland, USA, UAE
Balance Sheet Snapshot
Net Debt/Equity: Not specified
Reserves: Not specified
Current Assets/Liabilities: Current Assets ₹5,181 Cr, Current Liabilities ₹3,054 Cr (Sept-26)
Working Capital/Leverage Metrics: Not specified
Financial Health Insights: Strong cash flow generation with operating cash flow of ₹303 Cr (Sept-26)
Capex & Cash Flow Health
Capital Expenditure: Not specified for current period
Free Cash Flow: Not specified
Operating Cash Flow: ₹303 Cr (Net Cash from Operating Activities, Sept-26)
Net Debt Movement: Not specified
Investment Rationale: Focus on capacity expansion, technology upgrades, and strategic acquisitions
Strategic & R&D Initiatives
Investments in Innovation: 5 R&D centers across Gujarat, Tamil Nadu, Kansas USA, and Maharashtra
Expected impact on growth: Building platforms across business verticals of Agro, Personal Care, Pharma and Performance Materials
Strategic Rationale: Expanding into high-growth markets, reducing operational costs, building a globally integrated specialty chemicals platform
Industry Trends & Business Environment
Macro/Industry Trends: Growing demand for specialty chemicals across multiple end-use sectors
Impact on Company: Enabling expansion into new applications and strengthening capabilities across Pharmaceuticals, Performance Materials and other specialized segments
Management Commentary & Growth Outlook
Strategic Outlook: "H1 FY27 was marked by steady progress across our strategic priorities, expansion into new end markets and continued strengthening of our business portfolio. We are pleased to have achieved our highest-ever quarterly consolidated revenue during Q2 FY27, reflecting the resilience of our diversified business" - Mr. Anand S Desai, Managing Director
FY Guidance: Not specified
Market Share Targets: Not specified
Risks and Opportunities: Focus on disciplined execution, optimal utilization of capital employed, successful integration of strategic investments, and continuous enhancement of manufacturing and technological capabilities
ESG Updates
Received a Crisil ESG rating of 62 "Strong" and a Crisil Core ESG rating of 63 "Strong", improved from 54 "Adequate" in the previous year
On track to achieve best-in-class ESG standards by 2028
Energy net zero by 2028 on Scope 1+2 emissions
Acquisition Updates
- Acquired 50.07% controlling stake in Bliss GVS Pharma Limited (completed 28th September 2026)
- Acquired Jayhawk Fine Chemicals Corporation (US-based specialty chemicals company)
- Strengthened strategic investment in Tanfac Industries through participation in preferential issue
Contract Updates
Signed a six-year long-term supply contract with a leading US-based global specialty metal manufacturer
Total LOI/Contract value of ₹17,496 Crores across multiple agreements